164 related articles for article (PubMed ID: 27139372)
1. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression.
Feng Z; Wen H; Bi R; Ju X; Chen X; Yang W; Wu X
Sci Rep; 2016 May; 6():25408. PubMed ID: 27139372
[TBL] [Abstract][Full Text] [Related]
2. Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.
Tan J; Song C; Wang D; Hu Y; Liu D; Ma D; Gao Q
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33891016
[TBL] [Abstract][Full Text] [Related]
3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
Oncotarget; 2017 May; 8(20):32848-32855. PubMed ID: 28416763
[TBL] [Abstract][Full Text] [Related]
5. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers.
Witzel I; Graeser M; Karn T; Schmidt M; Wirtz R; Schütze D; Rausch A; Jänicke F; Milde-Langosch K; Müller V
J Cancer Res Clin Oncol; 2013 May; 139(5):809-16. PubMed ID: 23392859
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
Kensler KH; Poole EM; Heng YJ; Collins LC; Glass B; Beck AH; Hazra A; Rosner BA; Eliassen AH; Hankinson SE; Winer EP; Brown M; Tamimi RM
J Natl Cancer Inst; 2019 Jul; 111(7):700-708. PubMed ID: 30445651
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
[TBL] [Abstract][Full Text] [Related]
9. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
Ajani MA; Salami A; Awolude OA; Oluwasola AO
Pan Afr Med J; 2017; 27():259. PubMed ID: 29187928
[TBL] [Abstract][Full Text] [Related]
10. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.
Lau KM; Mok SC; Ho SM
Proc Natl Acad Sci U S A; 1999 May; 96(10):5722-7. PubMed ID: 10318951
[TBL] [Abstract][Full Text] [Related]
11. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
13. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
15. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptors in breast cancer: more than estrogen receptors.
Lamb CA; Vanzulli SI; Lanari C
Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
20. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS
Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]